Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/10/25
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual CongressGlobeNewsWire • 06/12/25
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 CongressGlobeNewsWire • 05/14/25
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/07/25
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to BuyZacks Investment Research • 03/14/25
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should KnowZacks Investment Research • 03/03/25
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 02/27/25
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 02/12/25
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/23/25
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga • 01/22/25
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/21/25
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA SubmissionGlobeNewsWire • 01/21/25
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)GlobeNewsWire • 01/21/25
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/09/24
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/09/24
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.GlobeNewsWire • 11/08/24
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated ApprovalGlobeNewsWire • 11/04/24
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)GlobeNewsWire • 11/01/24
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney WeekGlobeNewsWire • 10/25/24
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney WeekGlobeNewsWire • 10/11/24
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory OfficerGlobeNewsWire • 09/19/24